Calls of Note Part 4

- ThinkEquity views FDA's rejection of Nastech/Par Pharma's (NASDAQ:NSTK, -30%) version of nasal calcitonin as a positive for Unigene Laboratories (OTCBB:UGNE) shares since it indefinitely delays one potential competitor for Fortical. Firm recalls that there are at least two companies, including Nastech, pursuing approvals for salmon calcitonin and while both are currently held up by Novartis' patent litigation, an FDA rejection means that even if Novartis were to lose the case next year only one could enter the market unlike the two currently assumed in their model. Firm reiterates Buy rating on UGNE shares based on the Fortical ramp up and potential for pipeline advancement. Tgt stands at $7.

Notablecalls: For you gamblers out there.